full-year – Talk Bio

Actionable Insights Powered by AI

Vertex Pharmaceuticals Surpasses Q3 Expectations, Boosts Annual Revenue Forecast on Strong Cystic Fibrosis Sales

6 months ago talkbio0Tagged Casgevy, Cystic Fibrosis, earnings, full-year, Genetic Therapy, revenue guidance, Suzetrigine, Trikafta sales, vanzacaftor triple, VX-548

Vertex Pharmaceuticals, Q3 2024 earnings, Cystic fibrosis treatments, Trikafta sales, Full-year revenue guidance, Genetic therapies, Vanzacaftor triple, Suzetrigine (VX-548), Casgevy

Merck Reports Strong Q3 Results but Lowers Full-Year Sales Guidance

6 months ago talkbio0Tagged Advice, Capvaxive, full-year, Gardasil, Januvia, Keytruda, Merck, results, Sales - occupational activity, Winrevair

Merck, Q3 Results, Full-Year Sales Guidance, Keytruda, Gardasil, Januvia, Winrevair, Capvaxive